Development of bioactive materials for glioblastoma therapy

Yang, Jun; Li, Yan; Zhang, Tianlu; Zhang, Xin

doi:10.1016/j.bioactmat.2016.03.003

Cited by 16 publications

(11 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to their excellent spatial plasticity, polyesters were used to produce various scaffolds for bone tissue engineering via foaming [ [10] , [11] , [12] ], 3D-printing [ [13] , [14] , [15] ] and spinning [ [16] , [17] , [18] ]. The related polyesters mainly include polylactide (PLA) [ 10 , [19] , [20] , [21] ], poly(ε-caprolactone) (PCL) [ 14 , [22] , [23] , [24] ], poly(lactide-co-glycolide) (PLGA) [ [25] , [26] , [27] , [28] ], polyhydroxyalkanoates (PHAs) [ 10 , 11 ], and their mixtures [ 16 , 17 ]. Scaffolds composed of single polyesters can provide a reasonable three-dimensional (3D) space for cell adhesion, proliferation and migration, but they do not offer a desirable environment for osteogenic induction due to a lack of biologically functional substances [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

3D bioactive cell-free-scaffolds for in-vitro/in-vivo capture and directed osteoinduction of stem cells for bone tissue regeneration

Rahman

Peng

Zhao

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

Hydrophilic bone morphogenetic protein 2 (BMP2) is easily degraded and difficult to load onto hydrophobic carrier materials, which limits the application of polyester materials in bone tissue engineering. Based on soybean-lecithin as an adjuvant biosurfactant, we designed a novel cell-free-scaffold of polymer of poly(ε-caprolactone) and poly(lactide-co-glycolide)-co-polyetherimide with abundant entrapped and continuously released BMP2 for in vivo stem cell-capture and in situ osteogenic induction, avoiding the use of exogenous cells. The optimized bioactive osteo-polyester scaffold (BOPSC), i.e. SBMP-10SC, had a high BMP2 entrapment efficiency of 95.35%. Due to its higher porosity of 83.42%, higher water uptake ratio of 850%, and sustained BMP2 release with polymer degradation, BOPSCs were demonstrated to support excellent in vitro capture, proliferation, migration and osteogenic differentiation of mouse adipose derived mesenchymal stem cells (mADSCs), and performed much better than traditional BMP-10SCs with unmodified BMP2 and single polyester scaffolds (10SCs). Furthermore, in vivo capture and migration of stem cells and differentiation into osteoblasts was observed in mice implanted with BOPSCs without exogenous cells, which enabled allogeneic bone formation with a high bone mineral density and ratios of new bone volume to existing tissue volume after 6 months. The BOPSC is an advanced 3D cell-free platform with sustained BMP2 supply for in situ stem cell capture and osteoinduction in bone tissue engineering with potential for clinical translation.

show abstract

Section: Introductionmentioning

confidence: 99%

3D bioactive cell-free-scaffolds for in-vitro/in-vivo capture and directed osteoinduction of stem cells for bone tissue regeneration

Rahman

Peng

Zhao

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

show abstract

“…They have a structure consisting of a hydrophilic shell and a hydrophobic core capable of absorbing and encapsulating poorly soluble drugs. Therefore, they are widely used as drug delivery systems in various therapeutic areas, including cancer treatment, in particular glioblastoma (Morshed et al, 2013; Yang et al, 2016).…”

Section: Various Strategies For the Treatment Of Glioblastoma Using Bmentioning

confidence: 99%

The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment

Belousov

Titov

Shved

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

During cancer genesis, the extracellular matrix (ECM) in the human brain undergoes important transformations, starting to resemble embryonic brain cell milieu with a much denser structure. However, the stiffness of the tumor ECM does not preclude cancer cells from migration. The importance of the ECM role in normal brain tissue as well as in tumor homeostasis has engaged much effort in trials to implement ECM as a target and an instrument in the treatment of brain cancers. This review provides a detailed analysis of both experimental and applied approaches in combined therapy for gliomas in adults. In general, matrix materials for glioma treatment should have properties facilitating the simplest delivery into the body. Hence, to deliver an artificial implant directly into the operation cavity it should be packed into a gel form, while for bloodstream injections matrix needs to be in the form of polymer micelles, nanoparticles, etc. Furthermore, the delivered material should mimic biomechanical properties of the native tissue, support vital functions, and slow down or stop the proliferation of surrounding cells for a prolonged period. The authors propose a two-step approach aimed, on the one hand, at elimination of remaining cancer cells and on the other hand, at restoring normal brain tissue. Thereby, the first bioartificial matrix to be applied should have relatively low elastic modulus should be loaded with anticancer drugs, while the second material with a higher elastic modulus for neurite outgrowth support should contain specific factors stimulating neuroregeneration.

show abstract

“…Применение контрастных веществ также имеет свои недостатки, так как это требует многократных инъекций контрастного вещества, что может привести к дополнительной травме и увеличению метаболической нагрузки пациента. Кроме того, наличие гематоэнцефалического барьера серьезно ограничивает доставку большинства терапевтических агентов, таких как Dox, в ткани головного мозга [31]. Химиотерапевтические препараты, которые способны транспортироваться через ГЭБ, обычно неспособны эффективно находить опухоль для достижения нужных концентраций, необходимых для уничтожения опухолевых клеток без повреждения нормальной мозговой ткани.…”

Section: визуализация распределения наночастицunclassified

Nanoparticles: a New Approach to the Diagnosis and Treatment of Cerebral Glial Tumours

Gareev¹,

Beylerli²,

Павлов³

et al. 2019

Kreativnaâ hirurgiâ i onkologiâ

View full text Add to dashboard Cite

Glial tumors, and in particular anaplastic astrocytomas and glioblastoma multiforme (GBM), are aggressive brain tumors with poor prognosis and high recurrence rates. Current treatment strategies are based on open surgery, chemotherapy and radiation therapy. However, not a single one of these methods of treatment, alone or in combination, is effective in combating this disease, resulting in the average life expectancy following the diagnosis of under 15 months. Treatments are inefficient mainly due to the blood-brain barrier (BBB) that makes the delivery of drugs into the tumor mass difficult. With the development of nanotechnology the effectiveness of the drugs currently in use is on an increase and the reach to glial brain tumors is expanding. Nanoparticles are a preferred carrier of medicinal agents and dyes due to their size, availability of surface modification and the flexibility enabling the integration of several functional components into a single system. This makes it possible to direct the development of nanoparticles towards applications in the treatment and diagnosis of glial tumors. This dual approach helps to understand the location of the tumor tissue, bio-distribution of nanoparticles, and treatment progress and effectiveness. In order to improve the treatment and diagnosis approaches, various strategies can be applied to modify the surface of nanoparticles, including surface markers or so-called ligands and use the characteristics of the tumor microenvironment with specific targets which respond to specific stimuli. In this paper we review various strategies for the improvement of treatment and diagnosis of glial tumors, describe some surface markers and talk about opportunities for the introduction of nanoparticles into everyday clinical practice.

show abstract

Development of bioactive materials for glioblastoma therapy

Cited by 16 publications

References 98 publications

3D bioactive cell-free-scaffolds for in-vitro/in-vivo capture and directed osteoinduction of stem cells for bone tissue regeneration

3D bioactive cell-free-scaffolds for in-vitro/in-vivo capture and directed osteoinduction of stem cells for bone tissue regeneration

The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment

Nanoparticles: a New Approach to the Diagnosis and Treatment of Cerebral Glial Tumours

Contact Info

Product

Resources

About